Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis. Chief Executive Officer Michael Metzger said the company is now | ||
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | ||
Older | ||